Similar articles

• [Management of chronic myeloid leukemia].

  Kubuki Y. Kubuki Y. Rinsho Ketsueki. 2008 Oct;49(10):1401-10. Rinsho Ketsueki. 2008. PMID: 18833925 Review. Japanese. No abstract available.
• [Chronic myeloid leukemia 2008].

  Cervantes F. Cervantes F. Med Clin (Barc). 2008 Nov 15;131(17):658-9. doi: 10.1157/13128730. Med Clin (Barc). 2008. PMID: 19087793 Review. Spanish. No abstract available.
• NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.

  Goulden S, Sutcliffe F, Stevens A. Goulden S, et al. Lancet Oncol. 2012 Feb;13(2):127-8. doi: 10.1016/s1470-2045(12)70008-6. Lancet Oncol. 2012. PMID: 22403810 No abstract available.
• Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.

  Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M. Bumbea H, et al. J Med Life. 2010 Apr-Jun;3(2):162-6. J Med Life. 2010. PMID: 20968202 Free PMC article. Review.
• Drug developers unveil strategies aimed at imatinib-resistant CML.

  Goozner M. Goozner M. J Natl Cancer Inst. 2010 May 5;102(9):593-5. doi: 10.1093/jnci/djq163. Epub 2010 Apr 26. J Natl Cancer Inst. 2010. PMID: 20421566 No abstract available.